BioCentury
ARTICLE | Clinical News

Plasminogen activator inhibitor 2: Phase I data; Phase II

August 31, 1998 7:00 AM UTC

Biotech Australia said that Phase I safety testing of its inhibitor of tissue degradation showed a 25 percent average reduction in the size of ulcers at 28 days post-treatment. Patients in the trial r...